Recent studies are uncovering genetic and environmental factors at play in the earliest stages of rheumatoid arthritis and medications that are effective in treating juvenile idiopathic arthritis
Partners in Advancing Rheumatology
The REF is making great strides in advancing treatment and finding cures for rheumatic disease.
Systemic Juvenile Idiopathic Arthritis
Changing treatment paradigms in the biologic era
Growing Up Confident with Juvenile Idiopathic Arthritis
While juvenile arthritis can cause joint damage and limit function, rheumatologists strongly encourage children with JIA to live normal lives.
Patient Fact Sheet: Juvenile Idiopathic Arthritis
Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
CARRA
Working for Children with Rheumatic Diseases
New Guidance for Rheumatologists who Treat JIA
Evidence and consensus-based recommendations reflects current knowledge about initiation of therapy
Treat JIA Without Slowing Growth
Etanercept does not impede normal height and weight development in these patients
The Classification Challenge of Pediatric Spondylarthritis
Condition often confused with other disorders